• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病与心血管风险:病理生理机制及意义。

Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications.

机构信息

Laboratory of Experimental Medicine and Paediatrics (LEMP) - Gastroenterology & Hepatology, University of Antwerp, Wilrijk (Antwerp), Belgium; Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem (Antwerp), Belgium.

Laboratory of Experimental Medicine and Paediatrics (LEMP) - Gastroenterology & Hepatology, University of Antwerp, Wilrijk (Antwerp), Belgium.

出版信息

J Hepatol. 2016 Aug;65(2):425-43. doi: 10.1016/j.jhep.2016.04.005. Epub 2016 Jun 1.

DOI:10.1016/j.jhep.2016.04.005
PMID:27091791
Abstract

Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver diseases in the Western society and its prevalence is likely to rise even further. An increasing body of evidence shows that NAFLD is not only a potentially progressive liver disease, but also has systemic consequences. More specifically, evidence points out that NAFLD has to be considered as a significant independent risk factor for subclinical and clinical cardiovascular disease (CVD). Long-term follow-up studies demonstrate cardiovascular mortality to be the most important cause of death in NAFLD patients. Moreover, ample evidence associates NAFLD with endothelial dysfunction, increased pulse wave velocity, increased coronary arterial calcifications and increased carotid intima media thickness, all established markers for CVD. Despite of all this evidence, the mechanisms by which NAFLD causally contributes to CVD are not fully elucidated. Furthermore, an extensive overview of all potential pathophysiological mechanisms and the corresponding current data are lacking. In this review we summarise current knowledge, originating from fundamental and clinical research, that mechanistically links NAFLD to CVD. Subsequently, the impact of CVD on current clinical practice and future research in the area of NALFD are discussed.

摘要

非酒精性脂肪性肝病(NAFLD)已成为西方社会最常见的慢性肝病之一,其患病率可能进一步上升。越来越多的证据表明,NAFLD 不仅是一种潜在的进行性肝病,而且还具有全身性后果。更具体地说,有证据表明,NAFLD 必须被视为亚临床和临床心血管疾病(CVD)的重要独立危险因素。长期随访研究表明,心血管疾病死亡率是 NAFLD 患者死亡的最重要原因。此外,大量证据将 NAFLD 与内皮功能障碍、脉搏波速度增加、冠状动脉钙化增加和颈动脉内膜中层厚度增加相关联,这些都是 CVD 的既定标志物。尽管有这些证据,但 NAFLD 导致 CVD 的机制尚未完全阐明。此外,缺乏对所有潜在病理生理机制的广泛概述和相应的最新数据。在这篇综述中,我们总结了源自基础和临床研究的现有知识,这些知识从机制上将 NAFLD 与 CVD 联系起来。随后,讨论了 CVD 对当前临床实践和 NALFD 领域未来研究的影响。

相似文献

1
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications.非酒精性脂肪性肝病与心血管风险:病理生理机制及意义。
J Hepatol. 2016 Aug;65(2):425-43. doi: 10.1016/j.jhep.2016.04.005. Epub 2016 Jun 1.
2
A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?系统综述:非酒精性脂肪性肝病患者亚临床心血管疾病的负担和严重程度;我们应该重视吗?
Atherosclerosis. 2013 Oct;230(2):258-67. doi: 10.1016/j.atherosclerosis.2013.07.052. Epub 2013 Aug 9.
3
Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.糖尿病对非酒精性脂肪性肝病患者和非患者亚临床动脉粥样硬化及主要心血管事件的影响。
Diabetes Res Clin Pract. 2021 Jul;177:108873. doi: 10.1016/j.diabres.2021.108873. Epub 2021 May 26.
4
Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints.非酒精性脂肪性肝病:与心血管风险标志物及临床终点的关系。
Diabetes Res Clin Pract. 2018 Oct;144:144-152. doi: 10.1016/j.diabres.2018.08.011. Epub 2018 Aug 28.
5
[Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].[非酒精性脂肪性肝病患者的心血管风险]
Korean J Gastroenterol. 2017 Jun 25;69(6):333-340. doi: 10.4166/kjg.2017.69.6.333.
6
Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease.适量饮酒与非酒精性脂肪肝的亚临床心血管损伤无关,但与肝纤维化有关。
Alcohol. 2020 Dec;89:1-7. doi: 10.1016/j.alcohol.2020.07.010. Epub 2020 Jul 30.
7
Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.在非酒精性脂肪性肝病患者中,晚期肝纤维化与动脉粥样硬化相关。
Atherosclerosis. 2015 Jul;241(1):145-50. doi: 10.1016/j.atherosclerosis.2015.05.002. Epub 2015 May 6.
8
Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.与普通人群相比,非酒精性脂肪性肝病患者在10年随访期间颈动脉血管损伤和心血管事件的进展情况。
Atherosclerosis. 2016 Mar;246:208-13. doi: 10.1016/j.atherosclerosis.2016.01.016. Epub 2016 Jan 12.
9
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用,或与吡格列酮及其他药物联合使用,用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
10
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.非酒精性脂肪性肝病严重程度的改善与颈动脉内膜中层厚度进展的降低相关。
Atherosclerosis. 2016 Mar;246:13-20. doi: 10.1016/j.atherosclerosis.2015.12.028. Epub 2015 Dec 24.

引用本文的文献

1
Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease.整合肝脏与心脏健康:降低代谢相关脂肪性肝病患者的心血管风险
World J Cardiol. 2025 Jul 26;17(7):107751. doi: 10.4330/wjc.v17.i7.107751.
2
Association between the dietary index for gut microbiota and all-cause/cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease.肠道微生物群饮食指数与代谢功能障碍相关脂肪性肝病患者全因/心血管死亡率之间的关联
Diabetol Metab Syndr. 2025 Jul 11;17(1):263. doi: 10.1186/s13098-025-01846-x.
3
Association between liver fibrosis scores and cardiovascular disease in elderly based on NHANES 1999-2018.
基于1999 - 2018年美国国家健康与营养检查调查(NHANES)的老年人肝纤维化评分与心血管疾病之间的关联
Sci Rep. 2025 Jul 2;15(1):23334. doi: 10.1038/s41598-025-06871-4.
4
Targeting Phosphodiesterase 4 in Gastrointestinal and Liver Diseases: From Isoform-Specific Mechanisms to Precision Therapeutics.靶向磷酸二酯酶4治疗胃肠道和肝脏疾病:从亚型特异性机制到精准治疗
Biomedicines. 2025 May 23;13(6):1285. doi: 10.3390/biomedicines13061285.
5
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders.肠促胰岛素与代谢相关脂肪性肝病:内分泌与肝脏疾病的交汇点
Curr Obes Rep. 2025 Jun 25;14(1):56. doi: 10.1007/s13679-025-00646-8.
6
Metabolic dysfunction-associated steatotic liver disease and pregnancy.代谢功能障碍相关脂肪性肝病与妊娠
J Clin Invest. 2025 May 15;135(10). doi: 10.1172/JCI186426.
7
The risk factors for cardiovascular disease and chronic kidney disease in patients with nonalcoholic fatty liver disease in Saudi Arabia.沙特阿拉伯非酒精性脂肪性肝病患者心血管疾病和慢性肾脏病的危险因素。
Saudi Med J. 2025 May;46(5):478-490. doi: 10.15537/smj.2025.46.5.20240901.
8
Association Between High Sensitivity Cardiac Troponin and All-Cause and Cardiovascular Mortality in Adults at Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study.高敏心肌肌钙蛋白与有非酒精性脂肪性肝病风险的成年人全因死亡率和心血管死亡率之间的关联:一项队列研究
Glob Heart. 2025 Apr 29;20(1):40. doi: 10.5334/gh.1427. eCollection 2025.
9
Effect of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) on Left Ventricular Mechanics in Patients Without Overt Cardiac Disease: A Systematic Review and Meta-Analysis.代谢功能障碍相关脂肪性肝病(MASLD)对无明显心脏病患者左心室力学的影响:一项系统评价和荟萃分析
J Clin Med. 2025 Apr 15;14(8):2690. doi: 10.3390/jcm14082690.
10
Liver biomarkers as predictors of prognosis in heart failure with preserved ejection fraction: a systematic review and meta-analysis.肝脏生物标志物作为射血分数保留的心力衰竭预后预测指标:一项系统评价和荟萃分析。
BMC Cardiovasc Disord. 2025 Apr 2;25(1):244. doi: 10.1186/s12872-025-04647-2.